1921
Volume 73, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

We studied 52 patients with disseminated histoplasmosis, 30 with the acquired immunodeficiency syndrome (AIDS) (cohort 1) and 22 not co-infected with the human immunodeficiency virus (cohort 2). Demographic, clinical, laboratory, mycologic findings, as well as antifungal therapy and highly active antiretroviral (HAART), were analyzed. Skin lesions were significantly higher in cohort 1 than in cohort 2 ( = 0.001). Anemia, leukopenia, and an elevated erythrocyte sedimentation rate were also more pronounced in cohort 1 than in cohort 2 ( < 0.001. was isolated more often in cohort 1 than in cohort 2 ( < 0.05) patients, but antibodies to were detected more frequently in cohort 2 than in cohort 1 ( < 0.05). Itraconazole treatment was less effective in cohort 1 than in cohort 2 ( = 0.012). In cohort 1 patients, HAART improved response to antifungals when compared with individuals not given HAART ( = 0.003), who exhibited higher mortality rates ( = 0.025). Cohort 1 patients who were given dual antifungal and anti-retroviral therapies responded as well as the non-HIV patients in cohort 2, who were treated only with itraconazole. These results indicate the need to promote restoration of the immune system in patients with AIDS and histoplasmosis.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2005.73.576
2005-09-01
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/73/3/0730576.html?itemId=/content/journals/10.4269/ajtmh.2005.73.576&mimeType=html&fmt=ahah

References

  1. Wheat LJ, Kaufman CA, 2003. Histoplasmosis. Infect Dis Clin North Am 17 : 1–19.
  2. Kleiman MB, 2004. Histoplasmosis. Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Diseases. Philadelphia: W. B. Saunders, 2607–2629.
  3. Deepe GS, 2005. Histoplasma capsulatum. Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Sixth edition. Philadelphia: Churchill Livingstone, 2718–2733.
  4. Kaufman CA, 2003. Histoplasmosis. Dismukes WE, Pappas PG, Sobel JD, eds. Clinical Mycology. New York: Oxford University Press, 285–298.
  5. Tobón A, Franco L, Correa AL, Bedoya F, Ortega J, Soto M, 1997. Histoplasmosis en el adulto. Acta Med Colombiana 22 : 277–284.
  6. Arango M, Bedout C, Tobón AM, Restrepo A, Torrado E, Castañeda E, Sierra P, González GA, Panesso R, Cárdenas J, Estrada S, Jaramillo E, and the Colombian histoplasmosis study Group, 2000. Histoplasmosis en Colombia: Estudio interinstitucional. Informe Quincenal Epidemiol Nacional 5 : 119–123.
  7. Jiménez R, Urán M, De Bedout C, Arango M, Tobón AM, Cano LE, Restrepo A, 2002. Brote de histoplasmosis aguda en un grupo familiar: Identificación de la fuente de infección. Biomedica 22 : 155–159.
  8. Cano M, Hajjeh RA, 2001. The epidemiology of histoplasmosis: a review. Semin Respir Infect 16 : 109–188.
  9. Wheat J, 1996. Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol 7 : 7–18.
  10. Hajjeh RA, 1995. Disseminated histoplasmosis in people infected with human in immunodeficiency virus. Clin Infect Dis 21 : 108–110.
  11. Wheat LJ, Connolly-Stringfield PA, Baker RL, Curfman MD, Eads ME, Israel KS, Norris SA, Douglas FW, Zeckel ML, 1990. Disseminated histoplasmosis in the acquired immunodeficiency syndrome: clinical findings, diagnosis and treatment, and a review of the literature. Medicine (Baltimore) 69 : 361–374.
  12. Wheat LJ, 2003. Current diagnosis of histoplasmosis. Trends Microbiol 11 : 488–495.
  13. Hajjeh RA, Pappas PG, Henderson HD, Lancaster DM, Bamberger KJ, Skahan MA, Phelan,1 G. Cloud M, Holloway, Kauffman CA, Wheat LJ, the National Institute of Allergy and Infectious Diseases Mycoses Study Group, 2001. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected people. Clin Infect Dis 32 : 1215–1220.
  14. McKinsey DS, Spiegel RA, Hutwagner L, 1997. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors and pathophysiology. Clin Infect Dis 24 : 1195–1203.
  15. Wheat LJ, Chetchotisakd P, Williams B, Connolly P, Shutt K, Hajjeh R, 2000. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis 30 : 877–881.
  16. Couppie P, Sobesky M, Aznar C, Bichat S, Clyti E, Bissuel F, El Guedj M, Alvarez F, Demar M, Louvel D, Pradinaud R, Carme B, 2004. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis 38 : 134–138.
  17. Restrepo A, Gómez I, Cano LE, Arango MD, Gutiérrez F, Sanin A, Robledo MA, 1983. Post-therapy status of paracoccidioidomycosis patients treated with ketoconazole. Am J Med 74 : 53–57.
  18. Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kaufman C, 2000. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 30 : 688–695.
  19. Restrepo A, Robledo M, Ospina S, Restrepo M, Correa A, 1968. Distribution of paracoccidiodin sensitivity in Colombia. Am J Trop Med Hyg 17 : 25–37.
  20. Ordoñéz N, Tobón A, Arango M, de Bedout C, Gómez B, Castañeda E, Restrepo A, 1997. Brotes de histoplasmosis registrados en el área andina colombiana. Biomedica 17 : 105–111.
  21. Karimi K, Wheat J, Connolly P, Cloud G, Hajjeh R, Wheat E, Alves K, Lacaz CS, Keath E, 2002. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis 186 : 1655–1660.
  22. Pietrobon D, Negro-Marquínez L, Kilstein J, Galíndez J, Greca A, Battagliotti C, 2004. Histoplasmosis diseminada y sida en un hospital argentino: manifestaciones clínicas, diagnóstico y tratamiento. Enferm Infecc Microbiol Clin 22 : 156–159.
  23. Mandell WA, Goldberg DM, Neu HC, 1986. Histoplasmosis in patients with the acquired immune deficiency syndrome. Am J Med 81 : 974–978.
  24. Severo LC, Oliveira FM, Irion K, Porto NS, Londero AT, 2001. Histoplasmosis in Rio Grande do Sul, Brazil: a 21-year experience. Rev Inst Med Trop Sao Paulo 43 : 183–187
  25. Aberg JA, 2001. Reconstitution of immunity against opportunistic infections in the era of potent antiretroviral therapy. Volberding PA, Jacobson MA, eds. AIDS Clinical Review 2000/2001. New York: Marcel Dekker, 115–138.
  26. Sun HY, Chen MY, Hsieh SM, Hung CC, Chang SC, 2004. Successful discontinuation of secondary prophylaxis for histoplasmosis after highly active antiretroviral therapy. J Formos Med Assoc 103 : 546–548.
  27. Negroni R, Helou SH, López-Daneri G, Robles AM, Arechevala AI, Bianchi MH, 2004. Interruption of antifungal secondary prophylaxis in AIDS-related histoplasmosis. Rev Iberoam Micol 21 : 75–78.
  28. Gomez BL, Figueroa JI, Hamilton AJ, Diez S, Rojas M, Tobon A, Restrepo A, Hay RJ, 1999. Detection of the 70-kilodalton Histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-up. J Clin Microbiol 37 : 675–680.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2005.73.576
Loading
/content/journals/10.4269/ajtmh.2005.73.576
Loading

Data & Media loading...

  • Received : 24 Feb 2005
  • Accepted : 17 May 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error